Tesamorelin + Ipamorelin
Tesa+Ipa · long-acting GHRH + selective GHRP blend
FDA-APPROVED (COMPONENT) · FDA-APPROVED GHRH ANALOG (TESAMORELIN) + SELECTIVE GHRP (IPAMORELIN) BLEND
Mechanism of action
Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Researched effects
Visceral adiposity reduction (Tesamorelin signal); improved sleep and recovery; cleaner side-effect profile than CJC-DAC blends; favoured for HIV-lipodystrophy-adjacent body composition goals
Dosing reported in literature
1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Known concerns
Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)
No references match — clear filters.
Curated sources on file
3- 1.
- 2.
- 3.